Novo Nordisk A/S (ETR: NOV)

Market Cap	349.41B
Revenue (ttm)	36.28B
Net Income (ttm)	12.70B
Shares Out	n/a
EPS (ttm)	2.84
PE Ratio	27.51
Forward PE	n/a
Dividend	1.33 (1.32%)
Ex-Dividend Date	Aug 15, 2024

Volume	922,289
Open	99.70
Previous Close	99.54
Day's Range	71.62 - 99.91
52-Week Range	71.62 - 138.48
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 64,319
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NOV

Financial Performance

In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.

Financial numbers in DKK